|
1
|
Liu X, Gao Y, Lu Y, Zhang J, Li L and Yin
F: Oncogenes associated with drug resistance in ovarian cancer. J
Cancer Res Clin Oncol. 141:381–395. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Suh DH, Kim M, Kim HJ, Lee KH and Kim JW:
Major clinical research advances in gynecologic cancer in 2015. J
Gynecol Oncol. 27:e532016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
American Cancer Society, . Chemotherapy
for ovarian cancer. http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-treating-chemotherapy2014
February 4–2016
|
|
4
|
Huang H, Tong TT, Yau LF, Chen CY, Mi JN,
Wang JR and Jiang ZH: LC-MS based sphingolipidomic study on A2780
human ovarian cancer cell line and its taxol-resistant strain. Sci
Rep. 6:346842016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Galluzzi L, Senovilla L, Vitale I, Michels
J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms
of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hiss D: Optimizing molecular-targeted
therapies in ovarian cancer: The renewed surge of interest in
ovarian cancer biomarkers and cell signaling pathways. J Oncol.
2012:7379812012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim H, Park GS, Lee JE and Kim JH: A
leukotriene B4 receptor-2 is associated with paclitaxel resistance
in MCF-7/DOX breast cancer cells. Br J Cancer. 109:351–359. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim DK, Seo EJ, Choi EJ, Lee SI, Kwon YW,
Jang IH, Kim SC, Kim KH, Suh DS, Seong-Jang K, et al: Crucial role
of HMGA1 in the self-renewal and drug resistance of ovarian cancer
stem cells. Exp Mol Med. 48:e2552016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang WR, Zhang Y and Tang X: Shikonin
inhibits the proliferation of human lens epithelial cells by
inducing apoptosis through ROS and caspase-dependent pathway.
Molecules. 19:7785–7797. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu T, Ma C, Yang L, Wang W, Sui X, Zhao C
and Zu Y: Optimization of shikonin homogenate extraction from
Arnebia euchroma using response surface methodology. Molecules.
18:466–481. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Andújar I, Ríos JL, Giner RM and Recio MC:
Pharmacological properties of shikonin - A review of literature
since 2002. Planta Med. 79:1685–1697. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Han CT, Kim MJ, Moon SH, Jeon YR, Hwang
JS, Nam C, Park CW, Lee SH, Na JB, Park CS, et al: Acute and 28-day
subacute toxicity studies of hexane extracts of the roots of
Lithospermum erythrorhizon in Sprague-Dawley rats. Toxicol Res.
31:403–414. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
He G, He G, Zhou R, Pi Z, Zhu T, Jiang L
and Xie Y: Enhancement of cisplatin-induced colon cancer cells
apoptosis by shikonin, a natural inducer of ROS in vitro and in
vivo. Biochem Biophys Res Commun. 469:1075–1082. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jeung YJ, Kim HG, Ahn J, Lee HJ, Lee SB,
Won M, Jung CR, Im JY, Kim BK, Park SK, et al: Shikonin induces
apoptosis of lung cancer cells via activation of FOXO3a/EGR1/SIRT1
signaling antagonized by p300. Biochim Biophys Acta.
1863:2584–2593. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jing H, Sun W, Fan J, Zhang Y, Yang J, Jia
J, Li J, Guo J, Luo S and Zheng Y: Shikonin induces apoptosis of
HaCaT cells via the mitochondrial, Erk and Akt pathways. Mol Med
Rep. 13:3009–3016. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ko H, Kim SJ, Shim SH, Chang H and Ha CH:
Shikonin induces apoptotic cell death via regulation of p53 and
Nrf2 in AGS human stomach carcinoma cells. Biomol Ther (Seoul).
24:501–509. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lu D, Qian J, Li W, Feng Q, Pan S and
Zhang S: β-hydroxyisovaleryl-shikonin induces human cervical cancer
cell apoptosis via PI3K/AKT/mTOR signaling. Oncol Lett.
10:3434–3442. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tang X, Zhang C, Wei J, Fang Y, Zhao R and
Yu J: Apoptosis is induced by shikonin through the mitochondrial
signaling pathway. Mol Med Rep. 13:3668–3674. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Trivedi R, Müller GA, Rathore MS, Mishra
DP and Dihazi H: Anti-leukemic activity of shikonin: Role of ERP57
in shikonin induced apoptosis in acute myeloid leukemia. Cell
Physiol Biochem. 39:604–616. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wei Y, Li M, Cui S, Wang D, Zhang CY, Zen
K and Li L: Shikonin inhibits the proliferation of human breast
cancer cells by reducing tumor-derived exosomes. Molecules.
21(pii): E7772016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Christiansen JJ and Rajasekaran AK:
Reassessing epithelial to mesenchymal transition as a prerequisite
for carcinoma invasion and metastasis. Cancer Res. 66:8319–8326.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yin SY, Peng AP, Huang LT, Wang YT, Lan CW
and Yang NS: The phytochemical shikonin stimulates
epithelial-mesenchymal transition (EMT) in skin wound healing. Evid
Based Complement Alternat Med. 2013:2627962013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Thakur R, Trivedi R, Rastogi N, Singh M
and Mishra DP: Inhibition of STAT3, FAK and Src mediated signaling
reduces cancer stem cell load, tumorigenic potential and metastasis
in breast cancer. Sci Rep. 5:101942015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang FY, Hu Y, Que ZY, Wang P, Liu YH,
Wang ZH and Xue YX: Shikonin inhibits the migration and invasion of
human glioblastoma cells by targeting phosphorylated β-catenin and
phosphorylated PI3K/Akt: A potential mechanism for the anti-glioma
efficacy of a traditional Chinese herbal medicine. Int J Mol Sci.
16:23823–23848. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Carmichael J, DeGraff WG, Gazdar AF, Minna
JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated
colorimetric assay: Assessment of chemosensitivity testing. Cancer
Res. 47:936–942. 1987.PubMed/NCBI
|
|
26
|
Garrido C, Galluzzi L, Brunet M, Puig PE,
Didelot C and Kroemer G: Mechanisms of cytochrome c release from
mitochondria. Cell Death Differ. 13:1423–1433. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bi W, Wang Y, Sun G, Zhang X, Wei Y, Li L
and Wang X: Paclitaxel-resistant HeLa cells have up-regulated
levels of reactive oxygen species and increased expression of taxol
resistance gene 1. Pak J Pharm Sci. 27:871–878. 2014.PubMed/NCBI
|
|
28
|
Okon IS and Zou MH: Mitochondrial ROS and
cancer drug resistance: Implications for therapy. Pharmacol Res.
100:170–174. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wangpaichitr M, Wu C, Li YY, Nguyen DJM,
Kandemir H, Shah S, Chen S, Feun LG, Prince JS, Kuo MT and Savaraj
N: Exploiting ROS and metabolic differences to kill cisplatin
resistant lung cancer. Oncotarget. 8:49275–49292. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Peitsch MC, Polzar B, Stephan H, Crompton
T, MacDonald HR, Mannherz HG and Tschopp J: Characterization of the
endogenous deoxyribonuclease involved in nuclear DNA degradation
during apoptosis (programmed cell death). EMBO J. 12:371–377.
1993.PubMed/NCBI
|
|
31
|
Desagher S and Martinou JC: Mitochondria
as the central control point of apoptosis. Trends Cell Biol.
10:369–377. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sun Y, Liu WZ, Liu T, Feng X, Yang N and
Zhou HF: Signaling pathway of MAPK/ERK in cell proliferation,
differentiation, migration, senescence and apoptosis. J Recept
Signal Transduct Res. 35:600–604. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Habli Z, Toumieh G, Fatfat M, Rahal ON and
Gali-Muhtasib H: Emerging cytotoxic alkaloids in the battle against
cancer: Overview of molecular mechanisms. Molecules. 22(pii):
E2502017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xing K and Lisong S: Molecular targeted
therapy of cancer: The progress and future prospect. Front Lab Med.
1:69–75. 2017. View Article : Google Scholar
|
|
35
|
Chen ZS, Ling DJ, Zhang YD, Feng JX, Zhang
XY and Shi TS: Octamer-binding protein 4 affects the cell biology
and phenotypic transition of lung cancer cells involving
β-catenin/E-cadherin complex degradation. Mol Med Rep.
11:1851–1858. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Stewart CJ and McCluggage WG:
Epithelial-mesenchymal transition in carcinomas of the female
genital tract. Histopathology. 62:31–43. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Maeda M, Johnson KR and Wheelock MJ:
Cadherin switching: Essential for behavioral but not morphological
changes during an epithelium-to-mesenchyme transition. J Cell Sci.
118:873–887. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
DI Domenico M, Pierantoni GM, Feola A,
Esposito F, Laino L, DE Rosa A, Rullo R, Mazzotta M, Martano M,
Sanguedolce F, et al: Prognostic significance of N-Cadherin
expression in oral squamous cell carcinoma. Anticancer Res.
31:4211–4218. 2011.PubMed/NCBI
|
|
39
|
Liu LK, Jiang XY, Zhou XX, Wang DM, Song
XL and Jiang HB: Up-regulation of vimentin and aberrant expression
of E-cadherin/beta-catenin complex in oral squamous cell
carcinomas: Correlation with the clinicopathological features and
patient outcome. Mod Pathol. 23:213–224. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Powell CD, Paullin TR, Aoisa C, Menzie CJ,
Ubaldini A and Westerheide SD: The heat shock transcription factor
HSF1 induces ovarian cancer epithelial-mesenchymal transition in a
3D spheroid growth model. PLoS One. 11:e01683892016. View Article : Google Scholar : PubMed/NCBI
|
